TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. CHYM
4. USO
5. QCOM
6. IRT
7. ASO
8. PHVS
9. QQQ
10. UNFI

Go back to TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease
(NASDAQ: SGHT) Delayed: 8.06 -0.04 (0.49%)
Previous Close $8.10    52 Week High $ 
Open $8.01    52 Week Low $ 
Day High $8.08    P/E N/A 
Day Low $7.90    EPS $ 
Volume 11,265